Renalytix (RNLXD) Stock Price, News & Analysis

Company Overview

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

Key Stats

• Today's Range: $1.34 to $1.34
• 50-Day Range: $1.10 to $2.79
• 52-Week Range: $3.13 to $8.09
• Volume: 106 shs
• Average Volume: 2,432 shs
• Market Capitalization: $11.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RNLXD Stock Analysis - Frequently Asked Questions

How have RNLXD shares performed this year?

Renalytix's stock was trading at $3.62 at the beginning of the year. Since then, RNLXD stock has decreased by 63.0% and is now trading at $1.34.

How were Renalytix's earnings last quarter?

Renalytix Plc (OTCMKTS:RNLXD) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). The firm earned $0.46 million during the quarter, compared to the consensus estimate of $0.70 million.

How do I buy shares of Renalytix?

Shares of RNLXD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/14/2023
• Today: 5/05/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Computer and Technology
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:RNLXD
• CIK: 1811115
• Web: www.renalytixai.com
• Phone: 44-20-3139-2910
• Fax: N/A
• Employees: 100
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.21
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $3 million
• Price / Sales: 3.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.06) per share
• Price / Book: -1.26

Miscellaneous

• Outstanding Shares: 8,740,000
• Free Float: 7,822,000
• Market Cap: $11.71 million
• Optionable: Optionable
• Beta: 2.63